Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1, Irinotecan, and Oxaliplatin in Advanced Digestive Adenocarcinoma
NCT02387138Phase 1Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Apr 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tegafur in gastrointestinal adenocarcinoma (GIAC) (2 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoints: Dose Limiting Toxicities up to 5 years and Safety Profile up to 5 years. Started Apr 2014; status: completed.
02
Drugs
tegafur
03
Conditions
gastrointestinal adenocarcinoma (GIAC)
Beyond the preview
Go deeper on NCT02387138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387138.